THE LATEST
iCHOR news, press releases, and events
News & Press Releases
Understanding the Total Cost of Procedures for Thrombectomies
Hospitals routinely underestimate the true cost of thrombectomy because they focus on device price instead of the full episode of care. This article argues for a broader, “total cost” view that captures all direct and…
iCHOR Vascular, Simply Taking a Proven Surgical Fogarty Sweep into the Endovascular Labs
What inspired the creation of Ichor Vascular and the development of its core technology platform? The creation of Ichor Vascular was inspired by a clear clinical gap the founders observed while working with multiple thrombectomy…
iSWEEP: A Key Tool in the Thrombectomy Toolbox
A Simple Mechanical Option in a Complex Space iSweep provides a straightforward mechanical approach within the $24 billion thrombectomy market, which had previously been dominated by complex, capital intensive systems and multi component platforms. It…
Understanding the Benefits of Rep-Less Thrombectomy
What “Rep-Less” Thrombectomy Means In a traditional model, many thrombectomy procedures rely on having device reps in the room to guide product selection, setup, and troubleshooting. A rep-less approach is significantly different: Devices are designed…
A No Compromise Approach to Peripheral Thrombectomy
Innovative new technologies like iSWEEP, embodied in iART and iDVT, clearly demonstrate that peripheral thrombectomy does not have to compromise. No longer do practitioners need to live with the inherent shortcomings of existing aspiration systems,…
The Memo: iCHOR Vascular Simply Taking a Proven Surgical Fogarty Sweep Into the Endovascular Labs
Under the leadership of Co-Founder and CEO Tim Blair, ICHOR Vascular Inc. is advancing a new approach to treating peripheral vascular occlusions by converting one of surgery’s most proven techniques into a simple, minimally invasive…
Thrombectomy Opportunities in Peripheral Artery and Vein Sub-markets
Executive Summary for Investors and Strategic Partners The perception that thrombectomy is “crowded” often stems from evaluating the category in aggregate rather than by addressable sub-markets. For investors and strategic partners, this distinction is critical…
Is the Thrombectomy Market REALLY Overcrowded?
“Thrombectomy” is frequently treated as a single, monolithic category, leading to the misconception that there are too many devices and not enough room to stand out. In practice, thrombectomy spans distinct sub-markets defined by anatomy, indication, access…
Understanding the Total Cost of Procedures for Thrombectomies
Hospitals routinely underestimate the true cost of thrombectomy because they focus on device price instead of the full episode of care. This article argues for a broader, “total cost” view that captures all direct and…
iCHOR Vascular, Simply Taking a Proven Surgical Fogarty Sweep into the Endovascular Labs
What inspired the creation of Ichor Vascular and the development of its core technology platform? The creation of Ichor Vascular was inspired by a clear clinical gap the founders observed while working with multiple thrombectomy…
iSWEEP: A Key Tool in the Thrombectomy Toolbox
A Simple Mechanical Option in a Complex Space iSweep provides a straightforward mechanical approach within the $24 billion thrombectomy market, which had previously been dominated by complex, capital intensive systems and multi component platforms. It…
Understanding the Benefits of Rep-Less Thrombectomy
What “Rep-Less” Thrombectomy Means In a traditional model, many thrombectomy procedures rely on having device reps in the room to guide product selection, setup, and troubleshooting. A rep-less approach is significantly different: Devices are designed…
A No Compromise Approach to Peripheral Thrombectomy
Innovative new technologies like iSWEEP, embodied in iART and iDVT, clearly demonstrate that peripheral thrombectomy does not have to compromise. No longer do practitioners need to live with the inherent shortcomings of existing aspiration systems,…
The Memo: iCHOR Vascular Simply Taking a Proven Surgical Fogarty Sweep Into the Endovascular Labs
Under the leadership of Co-Founder and CEO Tim Blair, ICHOR Vascular Inc. is advancing a new approach to treating peripheral vascular occlusions by converting one of surgery’s most proven techniques into a simple, minimally invasive…
Thrombectomy Opportunities in Peripheral Artery and Vein Sub-markets
Executive Summary for Investors and Strategic Partners The perception that thrombectomy is “crowded” often stems from evaluating the category in aggregate rather than by addressable sub-markets. For investors and strategic partners, this distinction is critical…
Is the Thrombectomy Market REALLY Overcrowded?
“Thrombectomy” is frequently treated as a single, monolithic category, leading to the misconception that there are too many devices and not enough room to stand out. In practice, thrombectomy spans distinct sub-markets defined by anatomy, indication, access…
About iCHOR
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair. They identified an opportunity to develop new technologies to address these large unmet needs in treating peripheral vascular occlusions. This collaboration has lead to the development of the iSWEEP platform technology that has converted the tried and true Fogarty balloon sweep technique from an open surgery to a simple, minimally-invasive endovascular procedure.
Contact Us
Upcoming Events
The following are meetings and conferences that the iHCOR team will be attending. If you would like to meet with one of our team members, please email us at info@ichorvascular.com
